key: cord-1023298-rr0wj1mw authors: Meurens, François title: Flu RNA Vaccine: A Game Changer? date: 2020-12-14 journal: Vaccines (Basel) DOI: 10.3390/vaccines8040760 sha: 4d2d05daccd576d27f5a9d010a468a40444ad135 doc_id: 1023298 cord_uid: rr0wj1mw Influenza virus infection is a major One Health concern worldwide [...]. (4) potential adverse effects of live attenuated vaccines when they are used; (5) the interference of maternally-derived antibodies (MDA) with the induction of a protective immune response in infants; (6) the common use of adjuvants, especially for inactivated vaccines, not always very well-accepted by the population. Based on the current research, RNA vaccines developed against flu could broadly induce protective immune responses and could overcome some of the issues mentioned above [20, 21] . Antigenic drift-RNA segment reassortment resulting from coinfection events-is a major concern for health authorities because it can cause the rapid emergence of potentially pandemic influenza viruses [1, 22] . This is why the circulation of influenza viruses between their wild bird reservoirs and some mammalian hosts such as pigs which can act as "mixing vessels" [23] is closely monitored [22] . In the case of emergence, there is an absolute need for the fast development of effective vaccines widely available for the exposed populations. Two of the main advantages of RNA vaccines are that they can be easily updated once the genome sequence of the emerging influenza virus strain has been accurately identified, and they do not require toxic materials or cell cultures that could be contaminated with viruses. Besides these two major advantages, they do not require the systematic use of adjuvants, they do not exhibit any risk of reversion to virulence unlike many attenuated vaccines, and they commonly elicit well-balanced-humoral and cellular-immune responses. Regarding the contemporary drawbacks, a few can be identified. The main one is still the relatively low stability of the RNA-even though progress has been made-and the need for freezer conditions for the distribution and the administration, RNA being more likely to break apart above freezing temperatures [24] . Another limitation is the potential negative impact of type 1 and 3 interferons induced in response to vaccine RNA molecules on antigen expression [24] . Then, even if the risk of genomic integration is widely considered as null and is not a biosafety concern, eukaryotic cells have been shown to be able to provide, to some extent, reverse transcription activity [25] [26] [27] [28] . Further research on that eukaryotic reverse transcription activity, in the context of RNA vaccination, might be of interest for the scientific community [14] . Until now, in vitro transcribed (IVT) messenger RNA (mRNA) influenza virus vaccines were among the most studied RNA vaccines developed against infectious diseases in humans and animals. Two main types of mRNA vaccines have been developed against influenza virus infection: the non-replicating mRNA vaccines and the self-amplifying mRNA vaccines [20] , with possibly different types of RNA (prokaryotic, eukaryotic and transfer RNA amongst others) [29] . Both approaches are in the pipelines of the three current major players in the field of RNA vaccines: Moderna Therapeutics (Cambridge, MA, USA) [30] , EpiVax (Providence, RI, USA) and CureVac AG (Tübingen, Germany). Moderna, is working on a non-replicating mRNA vaccine with modified nucleosides incorporated associated to lipid nanoparticles (LNP) while CureVac AG, chose a strategy based on sequence-optimized unmodified mRNA-LNP. The EpiVax vaccine which targets highly pathogenic H7N9 subtype influenza virus is currently in phase 1 clinical trial. The impressive acceleration of RNA vaccine research caused by COVID-19 will probably continue to push forward the development of influenza virus RNA vaccines in the coming years. Besides RNA vaccines against flu and COVID-19, many others against rabies [31, 32] , Zika [33, 34] , Chikungunya [35] , and other pathogens [20] are also in the pipeline at various stages of development. Data about RNA vaccines are now accumulating very quickly and the first RNA vaccines have been released in the UK on December 2020 (and several countries are following). Are they going to be as effective and as convenient in their use than their competitors based on different approaches (see for instance [36] ) sometimes also very innovative and attractive? Will they bring enough advantages compared to other vaccines to be considered as real game changers? We currently-December 2020-still do not know, but we will for sure very soon. It is just a question of time. Fields Virology Bidirectional Human-Swine Transmission of Seasonal Influenza A(H1N1) pdm 09 Virus in Pig Herd Marshfield Influenza Study Group Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season Influenza vaccine effectiveness in Wisconsin during the 2007-2008 season: Comparison of interim and final results Prevention of Influenza Hospitalization Among Adults in the United States Influenza Vaccine Effectiveness in the United States During 2012-2013: Variable Protection by Age and Virus Type Influenza vaccine effectiveness in the 2011-2012 season: Protection against each circulating virus and the effect of prior vaccination on estimates DNA vaccines: Ready for prime time? RNA: The new revolution in nucleic acid vaccines DNA vaccines in veterinary use Recent advances in mRNA vaccine technology Self-amplifying RNA vaccines for infectious diseases Do RNA vaccines obviate the need for genotoxicity studies? Mutagenesis 2020 A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults An mRNA Vaccine against SARS-CoV-2-Preliminary Report Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults New Kids on the Block: RNA-Based Influenza Virus Vaccines mRNA Vaccines Encoding the HA Protein of Influenza A H1N1 Virus Delivered by Cationic Lipid Nanoparticles Induce Protective Immune Responses in Mice Lipkin, W.I.; Daszak, P. Prediction and prevention of the next pandemic zoonosis The pig as a mixing vessel for influenza viruses: Human and veterinary implications Advances in mRNA Vaccines for Infectious Diseases Human short-term repopulating cells have enhanced telomerase reverse transcriptase expression Human DNA polymerase η has reverse transcriptase activity in cellular environments Endogenous LINE-1 (Long Interspersed Nuclear Element-1) Reverse Transcriptase Activity in Platelets Controls Translational Events through RNA-DNA Hybrids Characterisation of cytoplasmic DNA complementary to non-retroviral RNA viruses in human cells Type of RNA Packed in VLPs Impacts IgG Class Switching-Implications for an Influenza Vaccine Design mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials Advances in RNA Vaccines for Preventive Indications: A Case Study of a Vaccine against Rabies Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: An open-label, non-randomised, prospective, first-in-human phase 1 clinical trial Modified mRNA vaccines protect against Zika virus infection Immunogenicity and Protection Efficacy of a Naked Self-Replicating mRNA-Based Zika Virus Vaccine Recent Progress in Vaccine Development against Chikungunya Virus A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial Acknowledgments: I thank Fanny Renois (Oniris) for the careful reading of the manuscript. The author declares no conflict of interest.Vaccines 2020, 8, 760